Patent ID: 8865666

Claim:
A diagnostic method for treating a subject having a tumor or cancer, which tumor or cancer overexpresses AKT kinase comprising: A. obtaining a biological sample from the subject; B. determining whether the sample overexpresses AKT kinase; C. if said sample overexpresses AKT kinase, 1. administering to said subject; i. at least one compound of formula I selected from the group consisting of the following compounds: wherein each R 2 ′, R 3 ′, and R 5 ′ is independently hydrogen; optionally substituted phosphate or phosphonate; mono-, di-, or triphosphate; acyl; lower acyl; alkyl; lower alkyl; amide; sulfonate ester; alkyl sulfonate ester; arylalkyl sulfonate ester; sulfonyl; methanesulfonyl; benzyl sulfonyl, wherein the phenyl group of said benzyl is optionally substituted with one or more halo, hydroxyl, amino, alkylamino, arylamino, alkoxy, aryloxy, nitro, cyano, sulfonic acid, sulfate, phosphonic acid, phosphate, or phosphonate; optionally substituted arylsulfonyl; a lipid; phospholipid; an amino acid; a carbohydrate; a peptide; or cholesterol; or other pharmaceutically acceptable leaving group that, in vivo, provides a compound of said formula I wherein R 2 ′, R 3 ′ or R 5 ′ is independently H or mono-, di- or tri-phosphate; wherein R x and R y are independently hydrogen; optionally substituted phosphate; acyl; lower acyl; amide; alkyl; lower alkyl; aromatic; polyoxyalkylene; polyethyleneglycol; optionally substituted arylsulfonyl; a lipid; a phospholipid; an amino acid; a carbohydrate; a peptide; or cholesterol; or other pharmaceutically acceptable leaving group; and wherein R 1 and R 2 each are independently H, optionally substituted straight chained, branched or cyclic alkyl, lower alkyl, alkenyl, or alkynyl, CO-alkyl, CO-alkenyl, CO-alkynyl, CO-aryl or heteroaryl, CO-alkoxyalkyl, CO-aryloxyalkyl, CO-substituted aryl, sulfonyl, alkylsulfonyl, arylsulfonyl, or aralkylsulfonyl; ii. a compound of the formula V: wherein R 1 , R 2 , R 3 , R 4 , and R 5 each are independently H, optionally halogenated, substituted straight chained, branched or cyclic alkyl, alkoxyl, alkenyl, or alkynyl, aryl, CO-alkyl, COalkenyl, CO-alkynyl, CO-aryl or heteroaryl, CO-alkoxyalkyl, CO-aryloxyalkyl, CO-substituted aryl, sulfonyl, alkylsulfonyl, arylsulfonyl, aralkylsulfonyl; and iii. a pharmaceutically acceptable carrier, wherein said treatment comprises administering 45 mg/m 2 or less of at least one compound of formula I over a one-hour intravenous infusion on days 1, 8, and 15 every 28 days until regression of the tumor or cancer cell is evident.